Circulating cell-free DNA for non-invasive cancer management

  • Caitlin M. Stewart
    Affiliations
    Marie-José and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 20, New York, NY 10065, USA

    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Search for articles by this author
  • Dana W.Y. Tsui
    Correspondence
    Corresponding author at: Marie-José and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 20, New York, NY 10065, USA.
    Affiliations
    Marie-José and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 20, New York, NY 10065, USA

    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Search for articles by this author

      Highlights

      • Cell-free nucleic acids in body fluids contain tumour fragments that can be profiled for prognostic and diagnostic information for the management of cancer.
      • cfDNA molecular profiling techniques, such as droplet digital PCR and next-generation sequencing, can be used to non-invasively guide treatment, track tumour evolution, detect the acquisition of resistance and monitor minimal residual disease.
      • cfDNA assays are now available for clinical use and more are rapidly being developed.
      Cell-free DNA (cfDNA) was first identified in human plasma in 1948 and is thought to be released from cells throughout the body into the circulatory system. In cancer, a portion of the cfDNA originates from tumour cells, referred to as circulating-tumour DNA (ctDNA), and can contain mutations corresponding to the patient's tumour, for instance specific TP53 alleles. Profiling of cfDNA has recently become an area of increasing clinical relevance in oncology, in particular due to advances in the sensitivity of molecular biology techniques and development of next generation sequencing technologies, as this allows tumour mutations to be identified and tracked non-invasively. This has opened up new possibilities for monitoring tumour evolution and acquisition of resistance, as well as for guiding treatment decisions when tumour biopsy tissue is insufficient or unavailable. In this review, we will discuss the biology of cell-free nucleic acids, methods of analysis, and the potential clinical uses of these techniques, as well as the on-going clinical development of ctDNA assays.

      Keywords

      To read this article in full you will need to make a payment

      Subscribe:

      Subscribe to Cancer Genetics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Jahr S.
        • et al.
        DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells.
        Cancer Res. 2001; 61: 1659-1665
        • Stroun M.
        • et al.
        About the possible origin and mechanism of circulating DNA apoptosis and active DNA release.
        Clin Chim Acta. 2001; 313: 139-142
        • Mandel P.
        • Metais P.
        Les acides nucleiques du plasma sanguin chez l'homme.
        C R Seances Soc Biol Fil. 1948; 142: 241-243
        • Zhang J.
        • et al.
        Presence of donor- and recipient-derived DNA in cell-free urine samples of renal transplantation recipients: urinary DNA chimerism.
        Clin Chem. 1999; 45: 1741-1746
        • Sidransky D.
        • et al.
        Identification of p53 gene mutations in bladder cancers and urine samples.
        Science. 1991; 252: 706-709
        • Rhodes C.H.
        • Honsinger C.
        • Sorenson G.D.
        Detection of tumor-derived DNA in cerebrospinal fluid.
        J Neuropathol Exp Neurol. 1994; 53: 364-368
        • Sriram K.B.
        • et al.
        Pleural fluid cell-free DNA integrity index to identify cytologically negative malignant pleural effusions including mesotheliomas.
        BMC Cancer. 2012; 12: 428
        • Wang Y.
        • et al.
        Detection of somatic mutations and HPV in the saliva and plasma of patients with head and neck squamous cell carcinomas.
        Sci Transl Med. 2015; 7: 293ra104
        • Mithani S.K.
        • et al.
        Mitochondrial resequencing arrays detect tumor-specific mutations in salivary rinses of patients with head and neck cancer.
        Clin Cancer Res. 2007; 13: 7335
        • Nadano D.
        • Yasuda T.
        • Kishi K.
        Measurement of deoxyribonuclease I activity in human tissues and body fluids by a single radial enzyme-diffusion method.
        Clin Chem. 1993; 39: 448-452
        • Tamkovich S.N.
        • et al.
        Circulating DNA and DNase activity in human blood.
        Ann N Y Acad Sci. 2006; 1075: 191-196
        • Yao W.
        • et al.
        Evaluation and comparison of in vitro degradation kinetics of DNA in serum, urine and saliva: a qualitative study.
        Gene. 2016; 590: 142-148
        • Chused T.M.
        • Steinberg A.D.
        • Talal N.
        The clearance and localization of nucleic acids by New Zealand and normal mice.
        Clin Exp Immunol. 1972; 12: 465-476
        • Thierry A.R.
        • et al.
        Origins, structures, and functions of circulating DNA in oncology.
        Cancer Metastasis Rev. 2016; 35: 347-376
        • Botezatu I.
        • et al.
        Genetic analysis of DNA excreted in urine: a new approach for detecting specific genomic DNA sequences from cells dying in an organism.
        Clin Chem. 2000; 46: 1078-1084
        • Bryzgunova O.E.
        • Laktionov P.P.
        Extracellular nucleic acids in urine: sources, structure, diagnostic potential.
        Acta Nat. 2015; 7: 48-54
        • Chan K.C.A.
        • et al.
        Quantitative analysis of the transrenal excretion of circulating EBV DNA in nasopharyngeal carcinoma patients.
        Clin Cancer Res. 2008; 14: 4809
        • Diehl F.
        • et al.
        Circulating mutant DNA to assess tumor dynamics.
        Nat Med. 2008; 14: 985-990
        • Lo Y.M.
        • et al.
        Rapid clearance of fetal DNA from maternal plasma.
        Am J Hum Genet. 1999; 64: 218-224
        • Yu S.C.
        • et al.
        High-resolution profiling of fetal DNA clearance from maternal plasma by massively parallel sequencing.
        Clin Chem. 2013; 59: 1228-1237
        • Jiang P.
        • Lo Y.M.
        The long and short of circulating cell-free DNA and the ins and outs of molecular diagnostics.
        Trends Genet. 2016; 32: 360-371
        • Giacona M.B.
        • et al.
        Cell-free DNA in human blood plasma: length measurements in patients with pancreatic cancer and healthy controls.
        Pancreas. 1998; 17: 89-97
        • Lo Y.M.
        • et al.
        Maternal plasma DNA sequencing reveals the genome-wide genetic and mutational profile of the fetus.
        Sci Transl Med. 2010; 2: 61ra91
        • Snyder M.W.
        • et al.
        Cell-free DNA comprises an in vivo nucleosome footprint that informs its tissues-of-origin.
        Cell. 2016; 164: 57-68
        • Sun K.
        • et al.
        Plasma DNA tissue mapping by genome-wide methylation sequencing for noninvasive prenatal, cancer, and transplantation assessments.
        Proc Natl Acad Sci. 2015; 112: E5503-E5512
        • Lehmann-Werman R.
        • et al.
        Identification of tissue-specific cell death using methylation patterns of circulating DNA.
        Proc Natl Acad Sci U S A. 2016; 113: E1826-E1834
        • Thierry A.R.
        • et al.
        Origin and quantification of circulating DNA in mice with human colorectal cancer xenografts.
        Nucleic Acids Res. 2010; 38: 6159-6175
        • Mouliere F.
        • et al.
        High fragmentation characterizes tumour-derived circulating DNA.
        PLOS ONE. 2011; 6: e23418
        • Underhill H.R.
        • et al.
        Fragment length of circulating tumor DNA.
        PLOS Genet. 2016; 12e1006162
        • Jiang P.
        • et al.
        Lengthening and shortening of plasma DNA in hepatocellular carcinoma patients.
        Proc Natl Acad Sci. 2015; 112: E1317-E1325
        • Yu S.C.Y.
        • et al.
        Size-based molecular diagnostics using plasma DNA for noninvasive prenatal testing.
        Proc Natl Acad Sci. 2014; 111: 8583-8588
        • Zheng Y.W.
        • et al.
        Nonhematopoietically derived DNA is shorter than hematopoietically derived DNA in plasma: a transplantation model.
        Clin Chem. 2012; 58: 549-558
        • Lo Y.M.
        • et al.
        Presence of fetal DNA in maternal plasma and serum.
        Lancet. 1997; 350: 485-487
        • Lo Y.M.
        • et al.
        Quantitative analysis of fetal DNA in maternal plasma and serum: implications for noninvasive prenatal diagnosis.
        Am J Hum Genet. 1998; 62: 768-775
        • Gorges T.M.
        • et al.
        Cancer therapy monitoring in xenografts by quantitative analysis of circulating tumor DNA.
        Biomarkers. 2012; 17: 498-506
        • Kamat A.A.
        • et al.
        Circulating cell-free DNA: a novel biomarker for response to therapy in ovarian carcinoma.
        Cancer Biol Ther. 2006; 5: 1369-1374
        • Nawroz H.
        • et al.
        Microsatellite alterations in serum DNA of head and neck cancer patients.
        Nat Med. 1996; 2: 1035-1037
        • Bettegowda C.
        • et al.
        Detection of circulating tumor DNA in early- and late-stage human malignancies.
        Sci Transl Med. 2014; 6: 224ra24
        • Parkinson C.A.
        • et al.
        Exploratory analysis of TP53 mutations in circulating tumour DNA as biomarkers of treatment response for patients with relapsed high-grade serous ovarian carcinoma: a retrospective study.
        PLoS Med. 2016; 13e1002198
        • Kostyuk S.V.
        • et al.
        Fragments of cell-free DNA increase transcription in human mesenchymal stem cells, activate TLR-dependent signal pathway, and suppress apoptosis.
        Biochem Suppl Ser B: Biomed Chem. 2012; 6: 68-74
        • Nishimoto S.
        • et al.
        Obesity-induced DNA released from adipocytes stimulates chronic adipose tissue inflammation and insulin resistance.
        Sci Adv. 2016; 2: 3
        • Dvorakova M.
        • et al.
        DNA released by leukemic cells contributes to the disruption of the bone marrow microenvironment.
        Oncogene. 2013; 32: 5201-5209
        • Gartler S.M.
        Cellular uptake of deoxyribonucleic acid by human tissue culture cells.
        Nature. 1959; 184: 1505-1506
        • Garcia-Olmo D.C.
        • et al.
        Cell-free nucleic acids circulating in the plasma of colorectal cancer patients induce the oncogenic transformation of susceptible cultured cells.
        Cancer Res. 2010; 70: 560-567
        • Sorenson G.D.
        • et al.
        Soluble normal and mutated DNA sequences from single-copy genes in human blood.
        Cancer Epidemiol Biomark Prev. 1994; 3: 67-71
        • Vogelstein B.
        • Kinzler K.W.
        Digital PCR.
        Proc Natl Acad Sci. 1999; 96: 9236-9241
        • Dressman D.
        • et al.
        Transforming single DNA molecules into fluorescent magnetic particles for detection and enumeration of genetic variations.
        Proc Natl Acad Sci. 2003; 100: 8817-8822
        • Schiavon G.
        • et al.
        Analysis of ESR1 mutation in circulating tumor DNA demonstrates evolution during therapy for metastatic breast cancer.
        Sci Transl Med. 2015; 7: 313ra182
        • Taly V.
        • et al.
        Multiplex picodroplet digital PCR to detect KRAS mutations in circulating DNA from the plasma of colorectal cancer patients.
        Clin Chem. 2013; 59: 1722
        • Sacher A.G.
        • et al.
        prospective validation of rapid plasma genotyping for the detection of EGFR and KRAS mutations in advanced lung cancer.
        JAMA Oncol. 2016; 2: 1014-1022
        • Baker M.
        Digital PCR hits its stride.
        Nat Meth. 2012; 9: 541-544
        • Yung T.K.
        • et al.
        Single-molecule detection of epidermal growth factor receptor mutations in plasma by microfluidics digital PCR in non-small cell lung cancer patients.
        Clin Cancer Res. 2009; 15: 2076-2084
        • Forshew T.
        • et al.
        Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA.
        Sci Transl Med. 2012; 4: 136ra68
        • Gale D.
        • et al.
        Analytical performance and validation of an enhanced TAm-Seq circulating tumor DNA sequencing assay.
        Inviata. 2016;
        • Newman A.M.
        • et al.
        An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage.
        Nat Med. 2014; 20: 548-554
        • De Mattos-Arruda L.
        • et al.
        Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: a proof-of-principle.
        Ann Oncol. 2014; 25: 1729-1735
        • Schwaederle M.
        • et al.
        Detection rate of actionable mutations in diverse cancers using a biopsy-free (blood) circulating tumor cell DNA assay.
        Oncotarget. 2016; 7: 9707-9717
        • Pal S.K.
        • et al.
        Evolution of circulating tumor DNA profile from first-line to subsequent therapy in metastatic renal cell carcinoma.
        Eur Urol. 2017; 2: 557-564
      1. Butler, T.M., et al., Exome sequencing of cell-free DNA from metastatic cancer patients identifies clinically actionable mutations distinct from primary disease. PLoS One, 2015. 10(8): p. e0136407.

        • Adalsteinsson V.A.
        • et al.
        Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors.
        Nat Commun. 2017; 8: 1324
        • Chicard M.
        • et al.
        Whole exome sequencing of cell-free DNA reveals temporo-spatial heterogeneity and identifies treatment-resistant clones in neuroblastoma.
        Clin Cancer Res. 2017; 24: 939-949
        • Murtaza M.
        • et al.
        Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA.
        Nature. 2013; 497: 108-112
        • Dietz S.
        • et al.
        Low input whole-exome sequencing to determine the representation of the tumor exome in circulating DNA of non-small cell lung cancer patients.
        PLoS One. 2016; 11e0161012
        • Kivioja T.
        • et al.
        Counting absolute numbers of molecules using unique molecular identifiers.
        Nat Methods. 2012; 9: 72-74
        • Kinde I.
        • et al.
        Detection and quantification of rare mutations with massively parallel sequencing.
        Proc Natl Acad Sci U S A. 2011; 108: 9530-9535
        • Newman A.M.
        • et al.
        Integrated digital error suppression for improved detection of circulating tumor DNA.
        Nat Biotechnol. 2016; 34: 547-555
        • Lanman R.B.
        • et al.
        Analytical and clinical validation of a digital sequencing panel for quantitative, highly accurate evaluation of cell-free circulating tumor DNA.
        PLOS ONE. 2015; 10e0140712
        • Ørntoft M.-B.W.
        • et al.
        Comparative analysis of 12 different kits for bisulfite conversion of circulating cell-free DNA.
        Epigenetics. 2017; 12: 626-636
        • Lecomte T.
        • et al.
        Detection of free-circulating tumor-associated DNA in plasma of colorectal cancer patients and its association with prognosis.
        Int J Cancer. 2002; 100: 542-548
        • Melnikov A.A.
        • et al.
        Methylation profile of circulating plasma DNA in patients with pancreatic cancer.
        J Surg Oncol. 2009; 99: 119-122
        • Kadam S.K.
        • Farmen M.
        • Brandt J.T.
        Quantitative measurement of cell-free plasma DNA and applications for detecting tumor genetic variation and promoter methylation in a clinical setting.
        J Mol Diagn. 2012; 14: 346-356
        • Chan K.C.
        • et al.
        Noninvasive detection of cancer-associated genome-wide hypomethylation and copy number aberrations by plasma DNA bisulfite sequencing.
        Proc Natl Acad Sci U S A. 2013; 110: 18761-18768
        • Zhao Y.
        • et al.
        Genome-wide methylation profiling of the different stages of hepatitis B virus-related hepatocellular carcinoma development in plasma cell-free DNA reveals potential biomarkers for early detection and high-risk monitoring of hepatocellular carcinoma.
        Clin Epigenet. 2014; 6: 30
        • Lo Y.M.
        • et al.
        Digital PCR for the molecular detection of fetal chromosomal aneuploidy.
        Proc Natl Acad Sci U S A. 2007; 104: 13116-13121
        • Miotke L.
        • et al.
        High sensitivity detection and quantitation of DNA copy number and single nucleotide variants with single color droplet digital PCR.
        Anal Chem. 2014; 86: 2618-2624
        • Gevensleben H.
        • et al.
        Noninvasive detection of HER2 amplification with plasma DNA digital PCR.
        Clin Cancer Res. 2013; 19: 3276-3284
        • Romanel A.
        • et al.
        Plasma AR and abiraterone-resistant prostate cancer.
        Sci Transl Med. 2015; 7: 312re10
        • Garcia-Murillas I.
        • Lambros M.
        • Turner N.C.
        Determination of HER2 amplification status on tumour DNA by digital PCR.
        PLOS ONE. 2013; 8: e83409
        • Chin S.F.
        • et al.
        Shallow whole genome sequencing for robust copy number profiling of formalin-fixed paraffin-embedded breast cancers.
        bioRxiv. 2017;
        • Heitzer E.
        • et al.
        Tumor-associated copy number changes in the circulation of patients with prostate cancer identified through whole-genome sequencing.
        Genome Med. 2013; 5: 30
        • Belic J.
        • et al.
        Rapid identification of plasma DNA samples with increased ctDNA levels by a modified FAST-SeqS approach.
        Clin Chem. 2015; 61: 838-849
        • Leary R.J.
        • et al.
        Detection of chromosomal alterations in the circulation of cancer patients with whole-genome sequencing.
        Sci Transl Med. 2012; 4: 162ra154
        • Chan K.C.A.
        • et al.
        Cancer genome scanning in plasma: detection of tumor-associated copy number aberrations, single-nucleotide variants, and tumoral heterogeneity by massively parallel sequencing.
        Clin Chem. 2013; 59: 211
        • Murtaza M.
        • et al.
        Multifocal clonal evolution characterized using circulating tumour DNA in a case of metastatic breast cancer.
        Nat Commun. 2015; 6: 8760
        • Jamal-Hanjani M.
        • et al.
        Detection of ubiquitous and heterogeneous mutations in cell-free DNA from patients with early-stage non-small-cell lung cancer.
        Ann Oncol. 2016; 27: 862-867
        • Cohen P.A.
        • et al.
        Abnormal plasma DNA profiles in early ovarian cancer using a non-invasive prenatal testing platform: implications for cancer screening.
        BMC Med. 2016; 14: 126
        • Lebofsky R.
        • et al.
        Circulating tumor DNA as a non-invasive substitute to metastasis biopsy for tumor genotyping and personalized medicine in a prospective trial across all tumor types.
        Mol Oncol. 2015; 9: 783-790
        • Frenel J.S.
        • et al.
        Serial next-generation sequencing of circulating cell-free DNA evaluating tumor clone response to molecularly targeted drug administration.
        Clin Cancer Res. 2015; 21: 4586-4596
        • Zonta E.
        • et al.
        Multiplex detection of rare mutations by picoliter droplet based digital PCR: sensitivity and specificity considerations.
        PLOS ONE. 2016; 11e0159094
        • Kidess E.
        • et al.
        Mutation profiling of tumor DNA from plasma and tumor tissue of colorectal cancer patients with a novel, high-sensitivity multiplexed mutation detection platform.
        Oncotarget. 2015; 6: 2549-2561
        • Thierry A.R.
        • et al.
        Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA.
        Nat Med. 2014; 20: 430-435
        • Beaver J.A.
        • et al.
        Detection of cancer DNA in plasma of patients with early-stage breast cancer.
        Clin Cancer Res. 2014; 20: 2643-2650
        • Diehl F.
        • et al.
        Detection and quantification of mutations in the plasma of patients with colorectal tumors.
        Proc Natl Acad Sci U S A. 2005; 102: 16368-16373
        • Sage Science and Rubicon Genomics
        Efficient generation of cfDNA libraries that are highly enriched in short fragments.
        in: Proceedings of the advances in genome biology and technology (AGBT), Scottsdale, Arizona Sage Science and Rubicon Genomics, 2016
        • Mouliere F.
        • et al.
        Selecting short DNA fragments in plasma improves detection of circulating tumour DNA.
        bioRxiv. 2017;
        • Medina Diaz I.
        • et al.
        Performance of streck cfDNA blood collection tubes for liquid biopsy testing.
        PLOS ONE. 2016; 11e0166354
        • Warton K.
        • et al.
        Evaluation of streck BCT and PAXgene stabilised blood collection tubes for cell-free circulating DNA studies in plasma.
        Mol Diagn Ther. 2017; 21: 563-570
        • Parpart-Li S.
        • et al.
        The effect of preservative and temperature on the analysis of circulating tumor DNA.
        Clin Cancer Res. 2017; 23: 2471-2477
        • Pan W.
        • et al.
        Brain tumor mutations detected in cerebral spinal fluid.
        Clin Chem. 2015; 61: 514-522
        • De Mattos-Arruda L.
        • et al.
        Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma.
        Nat Commun. 2015; 6: 8839
        • Pentsova E.I.
        • et al.
        Evaluating cancer of the central nervous system through next-generation sequencing of cerebrospinal fluid.
        J Clin Oncol. 2016; 34: 2404-2415
        • Birkenkamp-Demtroder K.
        • et al.
        Genomic alterations in liquid biopsies from patients with bladder cancer.
        Eur Urol. 2016; 70: 75-82
        • Mao L.
        • et al.
        Detection of oncogene mutations in sputum precedes diagnosis of lung cancer.
        Cancer Res. 1994; 54: 1634-1637
        • Gerlinger M.
        • et al.
        Intratumor heterogeneity and branched evolution revealed by multiregion sequencing.
        New Engl J Med. 2012; 366: 883-892
        • Yates L.R.
        • et al.
        Subclonal diversification of primary breast cancer revealed by multiregion sequencing.
        Nat Med. 2015; 21: 751-759
        • de Bruin E.C.
        • et al.
        Spatial and temporal diversity in genomic instability processes defines lung cancer evolution.
        Science. 2014; 346: 251-256
        • Zhang J.
        • et al.
        Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing.
        Science. 2014; 346: 256-259
        • Siravegna G.
        • et al.
        Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients.
        Nat Med. 2015; 21: 795-801
        • Oxnard G.R.
        • et al.
        Association between plasma genotyping and outcomes of treatment with osimertinib (AZD9291) in advanced non-small-cell lung cancer.
        J Clin Oncol. 2016; 34: 3375-3382
        • De Mattos-Arruda L.
        • et al.
        Establishing the origin of metastatic deposits in the setting of multiple primary malignancies: the role of massively parallel sequencing.
        Mol Oncol. 2014; 8: 150-158
        • Kuo Y.B.
        • et al.
        Comparison of KRAS mutation analysis of primary tumors and matched circulating cell-free DNA in plasmas of patients with colorectal cancer.
        Clin Chim Acta. 2014; 433: 284-289
        • Criscitiello C.
        • et al.
        Biopsy confirmation of metastatic sites in breast cancer patients: clinical impact and future perspectives.
        Breast Cancer Res. 2014; 16: 205
        • Turajlic S.
        • Swanton C.
        Metastasis as an evolutionary process.
        Science. 2016; 352: 169-175
        • Dawson S.J.
        • et al.
        Analysis of circulating tumor DNA to monitor metastatic breast cancer.
        N Engl J Med. 2013; 368: 1199-1209
        • Moran S.
        • et al.
        Epigenetic profiling to classify cancer of unknown primary: a multicentre, retrospective analysis.
        Lancet Oncol. 2016; 17: 1386-1395
        • Kang S.
        • et al.
        CancerLocator: non-invasive cancer diagnosis and tissue-of-origin prediction using methylation profiles of cell-free DNA.
        Genome Biol. 2017; 18: 53
        • Bianchi D.W.
        • et al.
        Noninvasive prenatal testing and incidental detection of occult maternal malignancies.
        Jama. 2015; 314: 162-169
        • Gautschi O.
        • et al.
        Origin and prognostic value of circulating KRAS mutations in lung cancer patients.
        Cancer Lett. 2007; 254: 265-273
        • Wang S.
        • et al.
        Potential clinical significance of a plasma-based KRAS mutation analysis in patients with advanced non-small cell lung cancer.
        Clin Cancer Res. 2010; 16: 1324-1330
        • Gray E.S.
        • et al.
        Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma.
        Oncotarget. 2015; 6: 42008-42018
        • Santiago-Walker A.
        • et al.
        Correlation of BRAF mutation status in circulating-free DNA and tumor and association with clinical outcome across four BRAFi and MEKi clinical trials.
        Clin Cancer Res. 2016; 22: 567-574
        • Zhuang R.
        • et al.
        The prognostic value of KRAS mutation by cell-free DNA in cancer patients: a systematic review and meta-analysis.
        PLOS ONE. 2017; 12e0182562
        • Marchetti A.
        • et al.
        Early prediction of response to tyrosine kinase inhibitors by quantification of EGFR mutations in plasma of NSCLC patients.
        J Thorac Oncol. 2015; 10: 1437-1443
        • Scherer F.
        • et al.
        Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA.
        Sci Transl Med. 2016; 8: 364ra155
        • Lipson E.J.
        • et al.
        Circulating tumor DNA analysis as a real-time method for monitoring tumor burden in melanoma patients undergoing treatment with immune checkpoint blockade.
        J Immunother Cancer. 2014; 2: 42
        • Oshiro C.
        • et al.
        PIK3CA mutations in serum DNA are predictive of recurrence in primary breast cancer patients.
        Breast Cancer Res Treat. 2015; 150: 299-307
        • Garcia-Murillas I.
        • et al.
        Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer.
        Sci Transl Med. 2015; 7: 302ra133
        • Olsson E.
        • et al.
        Serial monitoring of circulating tumor DNA in patients with primary breast cancer for detection of occult metastatic disease.
        EMBO Mol Med. 2015; 7: 1034-1047
        • Reinert T.
        • et al.
        Analysis of circulating tumour DNA to monitor disease burden following colorectal cancer surgery.
        Gut. 2016; 65: 625-634
        • Tie J.
        • et al.
        Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer.
        Sci Transl Med. 2016; 8: 346ra92
        • Leary R.J.
        • et al.
        Development of personalized tumor biomarkers using massively parallel sequencing.
        Sci transl med. 2010; 2 (pp. 20ra14–20ra14)
        • McBride D.J.
        • et al.
        Use of cancer-specific genomic rearrangements to quantify disease burden in plasma from patients with solid tumors.
        Gen Chromosom Cancer. 2010; 49: 1062-1069
        • Diaz L.A.
        • et al.
        The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers.
        Nature. 2012; 486: 537-540
        • Misale S.
        • et al.
        Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer.
        Nature. 2012; 486: 532-536
        • Chabon J.J.
        • et al.
        Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients.
        Nat Commun. 2016; 7: 11815
        • Morelli M.P.
        • et al.
        Characterizing the patterns of clonal selection in circulating tumor DNA from patients with colorectal cancer refractory to anti-EGFR treatment.
        Ann Oncol. 2015; 26: 731-736
        • Oxnard G.R.
        • et al.
        Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNA.
        Clin Cancer Res. 2014; 20: 1698-1705
        • Sorensen B.S.
        • et al.
        Monitoring of epidermal growth factor receptor tyrosine kinase inhibitor-sensitizing and resistance mutations in the plasma DNA of patients with advanced non-small cell lung cancer during treatment with erlotinib.
        Cancer. 2014; 120: 3896-3901
        • Thierry A.R.
        • et al.
        Circulating DNA demonstrates convergent evolution and common resistance mechanisms during treatment of colorectal cancer.
        Clin Cancer Res. 2017; 23: 4578-4591
        • Hyett J.A.
        • et al.
        Reduction in diagnostic and therapeutic interventions by non-invasive determination of fetal sex in early pregnancy.
        Prenat Diagn. 2005; 25: 1111-1116
        • Chiu R.W.
        • et al.
        Non-invasive prenatal assessment of trisomy 21 by multiplexed maternal plasma DNA sequencing: large scale validity study.
        Bmj. 2011; 342: c7401
        • Ehrich M.
        • et al.
        Noninvasive detection of fetal trisomy 21 by sequencing of DNA in maternal blood: a study in a clinical setting.
        Am J Obstet Gynecol. 2011; 204: 205.e1-205.e11
        • Palomaki G.E.
        • et al.
        DNA sequencing of maternal plasma to detect Down syndrome: an international clinical validation study.
        Genet Med. 2011; 13: 913-920
        • Hill M.
        • et al.
        Evaluation of non-invasive prenatal testing (NIPT) for aneuploidy in an NHS setting: a reliable accurate prenatal non-invasive diagnosis (RAPID) protocol.
        BMC Pregnancy Childbirth. 2014; 14: 229
        • Allyse M.
        • et al.
        Non-invasive prenatal testing: a review of international implementation and challenges.
        Int J Womens Health. 2015; 7: 113-126
        • Saito H.
        • et al.
        Prenatal DNA diagnosis of a single-gene disorder from maternal plasma.
        Lancet. 2000; 356: 1170
        • Normanno N.
        • et al.
        Guide to detecting epidermal growth factor receptor (EGFR) mutations in ctDNA of patients with advanced non-small-cell lung cancer.
        Oncotarget. 2017; 8: 12501-12516
        • Douillard J.Y.
        • et al.
        Gefitinib treatment in EGFR mutated caucasian NSCLC: circulating-free tumor DNA as a surrogate for determination of EGFR status.
        J Thorac Oncol. 2014; 9: 1345-1353
        • Han B.
        • et al.
        Determining the prevalence of EGFR mutations in Asian and Russian patients (pts) with advanced non-small-cell lung cancer (NSCLC) of adenocarcinoma (ADC) and non-ADC histology: IGNITE study.
        Ann Oncol. 2015; 26 (suppl_1): i29-i30
        • Reck M.
        • et al.
        ctDNA determination of EGFR mutation status in European and Japanese patients with advanced NSCLC: the ASSESS study.
        J Thorac Oncol. 2016; 11: 1682-1689
        • Vanderlaan P.A.
        • et al.
        Success and failure rates of tumor genotyping techniques in routine pathological samples with non-small-cell lung cancer.
        Lung Cancer. 2014; 84: 39-44
      2. European Medicines Agency. Iressa: public assessment report — product information. European Medicines Agency, 2017. EMA 2016 21 October, Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/001016/WC500036358.pdf.

      3. US Food and Drug Administration. Premarket approval P150044 — Cobas EGFR MUTATION TEST V2. US Food and Drug Administration, 2016. 21 October 2017 Available from: https://www.accessdata.fda.gov/cdrh_docs/pdf15/P150047a.pdf.

      4. European Medicines Agency. Tagrisso: public assessment report — product information. European Medicines Agency, 2017. EMA 2016 21 October 2017, Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/004124/WC500202022.pdf.

      5. Qiagen. Therascreen EGFR Plasma RGQ PCR Kit Handbook — Version 2. Qiagen, 2014. 21 October 2017 Available from: https://www.qiagen.com/at/resources/resourcedetail?id=d217c9ca-b9f6-4891-8c46-32b71e83d88a&lang=en.

      6. Remon, J., et al. Liquid biopsies for molecular profiling of mutations in non-small cell lung cancer (NSCLC) patients lacking tissue samples. Inivata 2016; Available from: http://inivata.com/wp-content/uploads/2016/09/MAP2016posterFINAL.pdf.

      7. US National Library of Medicine Next generation pErsonalized tX(Therapy) with plasma DNA trial-2 in refractory solid tumors (The NEXT-2 Trial). ClinicalTrials.gov, 2015.

        • Talasaz A.
        • et al.
        Ultra-high quality sequencing assay for comprehensive genetic panel analysis of rare tumor-derived circulating cell-free DNA.
        ASHG, Boston2013
      8. US National Library of Medicine. Monitoring plasma tumor dna in early-stage breast cancer. ClinicalTrials.gov. 2016 24 October 2017 Available from: https://clinicaltrials.gov/ct2/show/NCT02743910.

        • Gormally E.
        • et al.
        TP53 and KRAS2 mutations in plasma DNA of healthy subjects and subsequent cancer occurrence: a prospective study.
        Cancer Res. 2006; 66: 6871
        • Phallen J.
        • et al.
        Direct detection of early-stage cancers using circulating tumor DNA.
        Sci Transl Med. 2017; 9
        • Chan K.C.A.
        • et al.
        Analysis of plasma epstein–barr virus DNA to screen for nasopharyngeal cancer.
        New Eng J Med. 2017; 377: 513-522
        • Cheng S.H.
        • et al.
        Noninvasive prenatal testing by nanopore sequencing of maternal plasma DNA: feasibility assessment.
        Clin Chem. 2015; 61: 1305
        • Norris A.L.
        • et al.
        Nanopore sequencing detects structural variants in cancer.
        Cancer Biol Ther. 2016; 17: 246-253
        • Burnham P.
        • et al.
        Single-stranded DNA library preparation uncovers the origin and diversity of ultrashort cell-free DNA in plasma.
        Sci Rep. 2016; 6: 27859
        • Wu D.C.
        • Lambowitz A.M.
        Facile single-stranded DNA sequencing of human plasma DNA via thermostable group II intron reverse transcriptase template switching.
        Sci Rep. 2017; 7: 8421
        • Mouliere F.
        • et al.
        Multi-marker analysis of circulating cell-free DNA toward personalized medicine for colorectal cancer.
        Mol Oncol. 2014; 8: 927-941
        • Cheng T.H.T.
        • et al.
        Genomewide bisulfite sequencing reveals the origin and time-dependent fragmentation of urinary cfDNA.
        Clin Biochem. 2017;
        • Atamaniuk J.
        • et al.
        Increased concentrations of cell-free plasma DNA after exhaustive exercise.
        Clin Chem. 2004; 50: 1668
        • Fatouros I.G.
        • et al.
        Cell-free plasma DNA as a novel marker of aseptic inflammation severity related to exercise overtraining.
        Clin Chem. 2006; 52: 1820-1824
        • Gormally E.
        • et al.
        Circulating free DNA in plasma or serum as biomarker of carcinogenesis: practical aspects and biological significance.
        Mutat Res. 2007; 635: 105-117
        • Wan J.C.M.
        • et al.
        Liquid biopsies come of age: towards implementation of circulating tumour DNA.
        Nat Rev Cancer. 2017; 17: 223-238
        • Yu S.
        • et al.
        Tumor-derived exosomes in cancer progression and treatment failure.
        Oncotarget. 2015; 6: 37151-37168
        • Kahlert C.
        • Kalluri R.
        Exosomes in tumor microenvironment influence cancer progression and metastasis.
        J Mol Med (Berl). 2013; 91: 431-437
        • Yang S.
        • et al.
        Detection of mutant KRAS and TP53 DNA in circulating exosomes from healthy individuals and patients with pancreatic cancer.
        Cancer Biol Ther. 2017; 18: 158-165
        • Kahlert C.
        • et al.
        Identification of double-stranded genomic DNA spanning all chromosomes with mutated KRAS and p53 DNA in the serum exosomes of patients with pancreatic cancer.
        J Biolo Chem. 2014; 289: 3869-3875
        • Thakur B.K.
        • et al.
        Double-stranded DNA in exosomes: a novel biomarker in cancer detection.
        Cell Res. 2014; 24: 766-769
        • Sullivan R.J.
        • et al.
        Plasma-based monitoring of BRAF mutations during therapy for malignant melanoma (MM) using combined exosomal RNA and cell-free DNA analysis.
        J Clin Oncol. 2015; 33 (pp. 9017–9017)
        • Shao H.
        • et al.
        Chip-based analysis of exosomal mRNA mediating drug resistance in glioblastoma.
        Nat Commun. 2015; 6: 6999
        • Huang X.
        • et al.
        Characterization of human plasma-derived exosomal RNAs by deep sequencing.
        BMC Genom. 2013; 14: 319
        • Li M.
        • et al.
        Analysis of the RNA content of the exosomes derived from blood serum and urine and its potential as biomarkers.
        Philos Trans R Soc B: Biol Sci. 2014; 36920130502
        • Lunavat T.R.
        • et al.
        Small RNA deep sequencing discriminates subsets of extracellular vesicles released by melanoma cells–Evidence of unique microRNA cargos.
        RNA Biol. 2015; 12: 810-823
        • Matullo G.
        • Naccarati A.
        • Pardini B.
        MicroRNA expression profiling in bladder cancer: the challenge of next-generation sequencing in tissues and biofluids.
        Int J Cancer. 2016; 138: 2334-2345
        • Qin Y.
        • et al.
        High-throughput sequencing of human plasma RNA by using thermostable group II intron reverse transcriptases.
        RNA. 2016; 22: 111-128
        • Terrin L.
        • et al.
        Relationship between tumor and plasma levels of hTERT mRNA in patients with colorectal cancer: implications for monitoring of neoplastic disease.
        Clin Cancer Res. 2008; 14: 7444-7451
        • Pucciarelli S.
        • et al.
        Telomere-specific reverse transcriptase (hTERT) and cell-free RNA in plasma as predictors of pathologic tumor response in rectal cancer patients receiving neoadjuvant chemoradiotherapy.
        Ann Surg Oncol. 2012; 19: 3089-3096
        • Ng E.K.
        • et al.
        Presence of filterable and nonfilterable mRNA in the plasma of cancer patients and healthy individuals.
        Clin Chem. 2002; 48: 1212-1217
        • Nottingham R.M.
        • et al.
        RNA-seq of human reference RNA samples using a thermostable group II intron reverse transcriptase.
        RNA. 2016; 22: 597-613
        • Burgos K.L.
        • Van Keuren-Jensen K.
        RNA isolation for small RNA next-generation sequencing from acellular biofluids.
        Methods Mol Biol. 2014; 1182: 83-92
        • Yeri A.
        • et al.
        Total extracellular small RNA profiles from plasma, saliva, and urine of healthy subjects.
        Scientific Reports. 2017; 7: 44061
        • Khagi Y.
        • et al.
        Hypermutated circulating tumor DNA: correlation with response to checkpoint inhibitor–based immunotherapy.
        Clin Cancer Res. 2017; 23: 5729